2023
Homicsko K, Zygoura P, Tissot S, Popat S, Curioni-Fontecedro A, Dellaporta T, O’Brien M, Pope A, N.H. Shah R, Kammler R, Finn S, Coukos G, Peters S, Stahel RA. Association of tertiary lymphoid structures with outcomes from PD-1 inhibition in advanced malignant pleural mesothelioma.
ASCO 2023; Journal of Clinical Oncology 2023 41:16_suppl, e20545-e20545. https://doi.org/10.1200/JCO.2023.41.16_suppl.e20545
Soo RA, Dafni U, Han J-Y, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala Gonzalez MA, Coate L, Provencio Pulla M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn S, Peters S, Stahel RA, for the ETOP 10-16 BOOSTER Collaborators. Clinical impact of plasma EGFR analysis: results from the ETOP-BOOSTER randomized phase II trial. Presented at the ELCC 2023 in Copenhagen, Denmark.
2022
Homicsko K, Zygoura P, Tissot S, Norkin M, Popat S, Curioni-Fontecedro A, O’Brien MER, Pope T, Shah R, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RA. 11P Association of VISTA-expressing CD66b-positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma. ESMO Immuno-oncology and Tech, Dec 2022. https://doi.org/10.1016/j.iotech.2022.100116
Romano E, Castelo-Branco L, Tsourti Z, de Azambuja E, Gennatas S, Oliveira J, Rogado J, Sekacheva M, Susnjar S, Vinal Lozano D, Lee R, Khallaf SM, Dimopoulou G, Pradervand S, Arnold D, Harrington KJ, Michielin OA, Dafni U, Pentheroudakis G ,Peters S. LBA70 COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases. DOI:https://doi.org/10.1016/j.annonc.2022.08.076
Dafni U, Soo RA, Peters S, Tsourti Z, Vervita K, Han J, De Castro J, Coate L, Früh M, Hashemi SMS, Nadal E, Carcereny E, Angeles Sala González M, Bernabe Caro R, Provencio Pulla M, Cuffe S, Ruepp B, Roschitzki-Voser H, Rosell R, Stahel RA. 32P – Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis. Annals of Oncology (2022) 33 (suppl_2): S27-S70. Presented at the Virtual ELCC April 2022. https://oncologypro.esmo.org/meeting-resources/european-lung-cancer-congress/impact-of-smoking-status-on-the-relative-efficacy-of-the-egfr-tki-angiogenesis-inhibitor-combination-therapy-in-advanced-nsclc-a-systematic-review
2021
Martins-Branco D, Kassapian M, Debien V, Caparica R, Eiger D, Dafni U, Andriakopoulou C, El-Abed S, Izquierdo M, Vicente M, Chumsri S, Piccart-Gebhart M, Moreno-Aspitia A, Knop AS, Lombard J, de Azambuja E. The impact of erythropoietin administration concomitantly with adjuvant anti-HER2 treatment on the patients’ outcome: Sub-analysis of the ALTTO study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-14-05.
Soo RA, Han J-Y, Dimopoulou G, Chul Cho B, Ming Yeo C, Nadal E, Carcereny E, de Castro J, Sala MA, Reyes B, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S, Früh M, Roschitzki-Voser H, Ruepp B, Stahel R, Peters S, on behalf of the ETOP 10-16 BOOSTER Collaborators. A randomized phase II study of 2nd-line Osimertinib (osi) and bevacizumab (beva) versus osimertinib in advanced non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) and T790M mutations – results from the ETOP BOOSTER trial. Presented at the ESMO VIRTUAL PLENARY May 2021.
2020
Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard K, Untch M, Bellet Ezquerra M, Rosa DD, Moreno-Aspitia A, Piccart M, Dafni U, de Azambuja E. 221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO. Annals of Oncology, September 2020. https://doi.org/10.1016/j.annonc.2020.08.343
Opitz I, Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, Ampollini L, De Perrot M, Brcic L, Nadal E, Gray S, Aerts J, Verbeken E, Silini E, Zaeimi F, Samarzija M, LlatjoR, Tsimpoukis S, Von Der Thüsen J, Finn S, Monkhorst K, Marti N, Dimopoulou G, Kammler R, Peters S, Baas P, Stahel R, for the Mesoscape Consortium. Phosphorylated Ribosomal Protein S6, Correlation with Characteristics and Clinical Outcome in Patients with MPM: Results from ETOP Mesoscape. Presented at the WCLC 2020 in Singapore.
2019
Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R, O’Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur W D, López Castro R, García Campelo R, Roschitzki-Voser H, Ruepp B, Rusakiewicz S, Peters S, Stahel R A.
A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM)- results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Presented at the ESMO congress 2019 in Barcelona, Spain.
Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet A C, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel R A, Vansteenkiste J, De Ruysscher D.
Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC – Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial.
Presented at the ESMO congress 2019 in Barcelona, Spain.
Stahel R A, Curioni A, Rohrmann S, Dafni U, Sandner U, Andratschke N, Dimopoulou G, Guckenberger M, Kohler M, Matthes K, Schmitt-Opitz I, Weder W.
Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR).
Presented at the ESMO congress 2019 in Barcelona, Spain.
Opitz I, Bille A, Tsourti Z, Nackaerts K, Ampollini L, Perrot M, Brcic L, Nadal E, Gray S G, Aerts J, Verbeken E, Silini E M, Zaeimi F, Samarzija M, Llatjos R, Tsimpouki S, van der Thüsen J H, Finn S, Marti N, Dimopoulou G, Monkhorst K, Brunello A, Kammler R, Soltermann A, Falcoz P E, Baas P, Stahel R, for the ETOP Mesoscape and ESTS consortia.
Mesothelioma Realtime Data from Europe – ETOP Mesoscape / ESTS Database.
Presented at the WCLC congress 2019 in Barcelona, Spain.
Karlis D, Dafni U, Dimopoulou G. Exact methods for clinical trials with discrete outcome. Presented at ISCB 2019 in Leuven, Belgium and at EMR 2018 in Jerusalem.
2018
Peters S, Danson S, Hasan B, Reinmuth N, Majem M, Tournoy K, Mark M, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Massutí B, Coate L, von Moos R, Zielinski C, De Maio E, O’Brien M, Roschitzki-Voser H, Dafni U, Stahel R.
1385PD – A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC – the ETOP and EORTC SPLENDOUR trial.
Presented at the ESMO congress 2018 in Munich, Germany.
Curioni A, Felip E, Dafni U, Molina MA, Gautschi O, Peters S, Massutí B, Palmero R, Ponce S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Karachaliou N, Kammler R, Kassapian M, Roschitzki-Voser H, Stahel R, Rosell R.
1422P – Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.
Presented at the ESMO congress 2018 in Munich, Germany.
Peters S, De Ruysscher D, Dafni U, Felip E, Guckenberger M, Vansteenkiste JF, Huber RM, Nadal-Alforja E, Irigoyen A, Becker A, Piguet AC, Kassapian M, Gasca-Ruchti A, Martinez Marti A, Andratschke N, Lambrecht M, Belka C, Roschitzki-Voser H, Stahel RA.
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.
Presented at the ASCO Annual Meeting 2018 in Chicago, IL, USA.
Journal of Clinical Oncology 2018; 36, (Suppl. 15): 8510-8510.
DOI: 10.1200/JCO.2018.36.15_suppl.8510
2017
Thunnissen E, Dafni U, Bubendorf L, Warth A, Biernat W, Pokharel S, Dziadziuszko R, Dienemann H, Cheney R, Marti N, Kassapian M, Finn S, Kerr KM, Kammler R, Stahel RA, Peters S; Etop Lungscape
Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort.
Presented at the 18th IASLC WCLC 2017 in Yokohama, Japan.
Journal of Thoracic Oncology 2017; 12 (11 Suppl. 2): S1821-S1822.
https://doi.org/10.1016/j.jtho.2017.09.494
Kerr KM, Thunnissen E, Dafni U, Soltermann A, Finn SP, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EJM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Polydoropoulou V, Kammler R, Peters S, Stahel RA; Lungscape Consortium.
Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort.
Presented at the ESMO Congress 2017 in Madrid, Spain.
Annals of Oncology 2017; 28 (Suppl. 5): mdx390.002.
https://doi.org/10.1093/annonc/mdx390.002
Kerr KM, Thunnissen E, Dafni U, Soltermann A, Finn SP, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EJM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Bille Madsen A, Polydoropoulou V, Kammler R, Peters S, Stahel RA; ETOP Lungscape Consortium.
Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort.
Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA.
Journal of Clinical Oncology 2017; 35 (Suppl. 15): 8516.
http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.8516
Smit EF, Peters S, Dziadziuszko R, Dafni U, Wolf J, Wasąg B, Biernat W, Finn S, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E.
A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation. The ETOP NICHE trial.
Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA.
Journal of Clinical Oncology 2017; 35 (Suppl. 15): 9070.
http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.9070
Peters S, Stahel RA, Kassapian M, Guckenberger M, Felip E, De Langen AJ, Huber RM, Roschitzki-Voser H, Piguet AC, De Ruysscher D.
A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial.
Presented at the European Lung Cancer Conference 2017 in Geneva, Switzerland.
Annals of Oncology 2017; 28 (Suppl. 2): mdx092.009.
https://doi.org/10.1093/annonc/mdx092.009
Finn S, Letovanec I, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Peters S, Stahel R; ETOP Lungscape Consortium.
Evaluation of NGS and RT-PCR methods for ALK assessment in European NSCLC patients: Results from the ETOP Lungscape project.
Presented at the 17th IASLC WCLC 2016 in Vienna, Austria.
Journal of Thoracic Oncology. 2017; 12 (1 Suppl.): S501–S502.
https://doi.org/10.1016/j.jtho.2016.11.608
2016
De Ruysscher D, Pujol JL, Popat S, Reck M, Le Pechoux C, Liston A, Speiser D, Coukos G, Kammler R, Dafni U, Tsourti Z, Roschitzki H, Finlayson M, Piguet AC, Ruepp B, Maibach R, Stahel RA, Peters S.
STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT.
Presented at the ESMO Congress 2016 in Copenhagen, Denmark.
Annals of Oncology 2016; 27 (Suppl. 6): 1430TiP.
https://doi.org/10.1093/annonc/mdw389.08
Soltermann A, Rulle U, Dafni U, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel E-J, Bille Madsen L, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn S, Kammler R, Schulze K, Bubendorf L, Stahel RA; Lungscape Consortium.
Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort.
Presented at the ESMO Congress 2016 in Copenhagen, Denmark.
Annals of Oncology 2016; 27 (Suppl. 6): 1525P.
https://doi.org/10.1093/annonc/mdw392.07
Rosell R, Karachaliou N, Giménez-Capitán A, Codony-Servat C, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Ponce-Aix S, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Favaretto A, Kammler R, Dafni U, Tsourti Z, Molina-Vila MA, Stahel RA.
The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial.
Presented at the Annual Meeting of the AACR 2016, New Orleans, LA, USA.
American Association for Cancer Research, Cancer Research 2016; 76 (14 Suppl.): 269.
https://doi.org/10.1158/1538-7445.AM2016-269
2015
Stahel RA, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix SP, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Carcereny E, Sanchez Ronco M, Molina MA, Rosell R.
A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial.
Presented at the European Cancer Congress 2015 in Vienna, Austria.
European Journal of Cancer. 2015; 51 (Suppl. 3): S711-S712.
http://dx.doi.org/10.1016/S0959-8049(15)30068-X
Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Gately K, Biernat W, Vliegen L, Hernandez Losa J, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Molina MA, Shames DS, Peters S, Stahel R.
Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project.
Presented at the European Cancer Congress 2015 in Vienna, Austria.
European Journal of Cancer 2015; 51 (Suppl. 3): S595-S596.
http://dx.doi.org/10.1016/S0959-8049(16)31647-1
Bubendorf L, Dafni U, Finn SP, Warth A, Savic S, Thunnissen E, Sejda A, Verbeken EK, Tischler V, Marchetti A, Sansano I, Speel EJM, Cheney R, Nonaka D, Monkhorst K, Di Lorito A, Consuelo Calabuig M, Reidy M, Hager H, Mathieson W, Martorell M, Baas P, Dienemann H, Smit EF, Blackhall FH Dingemans AMC, Felip E, Adjei A, Meldgaard P, Weder W, Vansteenkiste J, Dziadziuszko R, Tsourti Z, Kerr KM, Schulze K, Das-Gupta A, Peters S, Stahel RA.
Prevalence and clinical association of MET gene amplification in patients with NSCLC: Results from the ETOP Lungscape Project.
Presented at the 16th WCLC 2015 in Denver, CO, USA.
Journal of Thoracic Oncology 2015; 10 (9 Suppl. 2): S247.
http://dx.doi.org/10.1016/S1556-0864(16)30010-7
Letovanec I, Peters S, Tsourti Z, Finn SP, Soltermann A, Bubendorf L, Speel EJM, Marchetti A, Nonaka D, Hager H, Martorell M, Monkhorst K, Sejda A, Cheney R, Sansano I, Verbeken EK, Tischler V, Savic S, Di Lorito A, Consuelo Calabuig M, Felip E, Adjei A, Warth A, Baas P, Meldgaard P, Blackhall FH, Dingemans AMC, Dienemann H, Dziadziuszko R, Vansteenkiste J, Kammler R, Dafni U, Kerr KM, Thunnissen E, Stahel RA.
Evaluation of RT-PCR methodology for ALK assessment in patients with NSCLC in Europe: Results from the ETOP Lungscape Project.
Presented at the 16th WCLC 2015 in Denver, CO, USA.
Journal of Thoracic Oncology 2015; 10 (9 Suppl. 2): S693-S694.
http://dx.doi.org/10.1016/S1556-0864(16)30012-0
Peters S, Smit EF, Dafni U, Aix SP, Massuti B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Floriani IC, Kassapian M, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Zielinski C, Gregorc V, Stahel RA; EMPHASIS Collaborative Group.
Randomized phase III trial of Erlotinib vs. Docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum-based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS trial.
Presented at the ASCO Annual Meeting 2015 in Chicago, IL, USA.
Journal of Clinical Oncology 2015; 33 (Suppl. 15): 8049.
http://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.8049
Filipits M, Gnant M, Dafni U, Polydoropoulou V, Hills MJ, Leyland-Jones B, Piccart-Gebhart M and Dowsett M.
TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial.
Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (2014) in San Antonio, TX, USA.
American Association for Cancer Research, Cancer Research 2015; 75 (Suppl. 9): 269: Abstract P5-18-01.
http://doi.org/10.1158/1538-7445.SABCS14-P5-18-01
Willis S, Polydoropoulou V, Tsourti Z, Dafni U, Young B, Long B, De P, Dey N, Williams C, Dowsett M and Leyland-Jones B.
Exploratory analysis of single gene predictive biomarkers in TransHERA DASL cohort reveals that C8A mRNA expression is prognostic of outcome and predictive of benefit of trastuzumab.
Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (2014) in San Antonio, TX, USA.
American Association for Cancer Research, Cancer Research 2015; 75 (Suppl. 9): 269: Abstract P3-06-02.
http://doi.org/10.1158/1538-7445.SABCS14-P3-06-02
2014
Bubendorf L, Dafni U, Tischler V, Finn SP, Biernat W, Verbeken E, Hager H, Murtra N, Thunnissen E, Nonaka D, Warth A, Speel EJM, Savic S, Martorell M, Tsourti Z, Schulze K, Das Gupta A, Kerr KM, Peters S, and Stahel RA.
Prevalence and clinical outcomes for patients with MET protein expression in patients with non-small cell lung cancer in Europe: Results from the European Thoracic Oncology Platform Lungscape Project.
Presented at the ESMO Congress 2014 in Madrid, Spain.
Annals of Oncology 2014; 25 (Suppl. 4): iv418.
https://doi.org/10.1093/annonc/mdu348.5
Willis S, Harris R, Karlis D, Polydoropoulou V, Dafni U, Long B, Young B, Dowsett M and Leyland-Jones B.
Prognostic indicators of APOBEC family members for disease-free survival in the observation arm of TransHERA DASL cohort.
Presented at the 9th European Breast Cancer Conference (EBCC9) 2014 in Glasgow, Scotland
European Journal of Cancer 2014; 50 (Suppl. 2): S204.
http://dx.doi.org/10.1016/S0959-8049(14)70103-0
2013
Kerr KM, Thunnissen E, Blackhall FH, Dafni U, Bubendorf L, Hager H, Soltermann A, O’Byrne KJ, Marchetti A, Dooms C, Sejda A, Sansano I, Nonaka D, Cheney R, De Jong J, Speel EJM, Jantus-Lewintre E, Zhang YJ, Stahel RA, and Peters S.
ALK immunohistochemistry and fluorescence in-situ hybridization in lung adenocarcinomas from the ETOP Lungscape tumour cohort.
Presented at 15th WCLC 2013 in Sydney, Australia.
Journal of Thoracic Oncology 2013; 8 (11 Suppl. 2): S318-319.
https://doi.org/10.1097/01.JTO.0000438438.14562.c8
Peters S, Weder W, Meldgaard P, O’Byrne KJ, Wrona A, Dooms C, Hernandez-Losa J, Marchetti A, Nicolson M, Tan Q, Smit EF, Dingemans AMC, Savic S, Blackhall FH, Baas P, Jantus-Lewintre E, Kerr KM, Dafni U, Rosell R, Stahel RA, European Thoracic Oncology Platform (ETOP).
The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer.
Presented at the ASCO Annual Meeting 2013 in Chicago, IL, USA.
Journal of Clinical Oncology 2013; 31 (Suppl. 15): 7514.
http://ascopubs.org/doi/10.1200/jco.2013.31.15_suppl.7514
2012
Peters S, Dafni O, Bubendorf L, Meldgaard P, O’Byrne KJ, Wrona A, Weder W, Canela M, Malatesta S, Vansteenkiste JF, Dingemans AMC, Nicolson MC, Savic S, Baas P, Peck R, Lu S, Smit EF, Jantus-Lewintre E, Rosell R, and Stahel RA; on behalf of ETOP.
The European Thoracic Oncology Platform Lungscape project. A way to bridge non-small cell lung cancer molecular characteristics and clinical data.
Presented at the ESMO Congress 2012 in Vienna, Austria.
Annals of Oncology 2012; 23 (Suppl. 9): ix385.
http://doi.org/10.1093/annonc/mds407
Blackhall FH, Peters S, Kerr KM, O’Byrne KJ, Hager H, Sejda A, Soltermann A, Dooms C, Felip E, Marchetti A, Speel EJM, Price N, Savic S, De Jong J, Martorell M, Thunnissen E, Bubendorf L, Dafni O, Rosell R, and Stahel RA; on behalf of ETOP.
Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: Preliminary results from the European Thoracic Oncology Platform Lungscape project.
Presented at the ESMO Congress 2012 in Vienna, Austria.
Annals of Oncology 2012; 23 (Suppl. 9): ix73.
http://doi.org/10.1093/annonc/mds391
Stahel RA, Blackhall FH, Peters S, Bubendorf L, Dafni O, Kerr KM, Taron M, Thunnissen E, Weder W, and Rosell R.
The Lungscape project.
Presented at ELCC 2012 in Geneva, Switzerland.
Journal of Thoracic Oncology 2012; 7 (6 Suppl. 1): S13.
http://dx.doi.org/10.1097/JTO.0b013e318253d2ff
Stahel RA, Peters S, Blackhall FH, Bubendorf L, Dafni U, Kerr KM, Taron M, Thunnissen E, Weder W, Smit E, and Rosell R.
ETOP activity in the field of biomarkers and predictors.
Presented at BTOG 2012 in Dublin, Ireland.
Lung Cancer 2012; 77 (Suppl. 1): S16-S17.
http://dx.doi.org/10.1016/j.lungcan.2012.05.028
2011
Hills M, Filipits M, Salter J, Dafni U, Gelber RD, Piccart M, Gnant M, Smith BR, Leyland-Jones B, Dowsett M.
TransHERA: Analysis of PTEN, IGF-1R and Stathmin as putative prognostic/predictive markers in HER2-positive early breast cancer (BC) patients treated with 1-year of trastuzumab.
Presented at Conference on Improving Care and Knowledge through Translational Research (IMPAKT) Breast Cancer, Brussels, BELGIUM, 2011.
Annals of Oncology 2011, 22 (Suppl. 2): ii45.
http://doi.org/10.1093/annonc/mdr086